Seres Therapeutics Inc. (NASDAQ:MCRB) shares traded up 4% during trading on Monday . The company traded as high as $10.08 and last traded at $9.98, with a volume of 597,149 shares changing hands. The stock had previously closed at $9.60.

A number of research analysts recently commented on the stock. Canaccord Genuity reaffirmed a “buy” rating on shares of Seres Therapeutics in a research report on Sunday, May 29th. Cowen and Company reaffirmed a “buy” rating on shares of Seres Therapeutics in a research report on Tuesday, July 19th. FBR & Co reissued a “buy” rating on shares of Seres Therapeutics in a research report on Monday, May 2nd. HC Wainwright began coverage on shares of Seres Therapeutics in a research report on Friday, July 29th. They set a “buy” rating and a $50.00 price objective on the stock. Finally, Zacks Investment Research downgraded shares of Seres Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday, May 18th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and six have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $34.43.

The stock’s market capitalization is $382.94 million. The company has a 50 day moving average of $27.64 and a 200-day moving average of $27.37.

Seres Therapeutics (NASDAQ:MCRB) last posted its quarterly earnings results on Monday, May 16th. The company reported ($0.50) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.48) by $0.02. The company had revenue of $2.71 million for the quarter, compared to analysts’ expectations of $1.25 million. On average, equities analysts expect that Seres Therapeutics Inc. will post ($1.86) earnings per share for the current fiscal year.

In related news, CEO Roger Pomerantz sold 9,801 shares of the company’s stock in a transaction on Tuesday, May 24th. The shares were sold at an average price of $30.00, for a total value of $294,030.00. Following the sale, the chief executive officer now directly owns 193,493 shares of the company’s stock, valued at $5,804,790. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, major shareholder Ventures Fund 2007 L. Flagship sold 1,000,000 shares of the company’s stock in a transaction on Wednesday, May 25th. The shares were sold at an average price of $27.60, for a total transaction of $27,600,000.00. The disclosure for this sale can be found here.

A number of hedge funds recently bought and sold shares of the stock. Morgan Stanley boosted its stake in Seres Therapeutics by 225.3% in the fourth quarter. Morgan Stanley now owns 33,758 shares of the company’s stock valued at $1,185,000 after buying an additional 23,381 shares in the last quarter. BlackRock Advisors LLC boosted its stake in Seres Therapeutics by 0.7% in the fourth quarter. BlackRock Advisors LLC now owns 340,871 shares of the company’s stock valued at $11,962,000 after buying an additional 2,443 shares in the last quarter. Finally, Jennison Associates LLC boosted its stake in Seres Therapeutics by 1.9% in the fourth quarter. Jennison Associates LLC now owns 398,959 shares of the company’s stock valued at $13,999,000 after buying an additional 7,259 shares in the last quarter.

Seres Therapeutics, Inc is a microbiome therapeutics platform company. The Company is engaged in developing a range of biological drugs, Ecobiotic microbiome therapeutics. It is focused on implementing its microbiome therapeutics platform to develop Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome in the human body.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.